贝伐-话题@MedSci

#贝伐#

228篇内容 | 4144人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1477112, encodeId=87cb14e711233, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, objectType=article, longId=294716, objectId=db94294e16ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db94294e16ed, replyNumber=0, likeNumber=89, createdTime=2022-01-27, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db94294e16ed, moduleTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db94294e16ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477111, encodeId=bb7814e71117b, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, objectType=article, longId=293790, objectId=a320293e9099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a320293e9099, replyNumber=0, likeNumber=61, createdTime=2022-01-12, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a320293e9099, moduleTitle=Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a320293e9099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477109, encodeId=155514e710940, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Chin J Cancer Res：中肿徐瑞华教授团队IV期观察性研究：评估中国转移性结直肠癌使用化疗联合贝伐珠单抗治疗的真实世界疗效和安全性, objectType=article, longId=292555, objectId=6a7d292555c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a7d292555c6, replyNumber=0, likeNumber=60, createdTime=2021-12-24, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a7d292555c6, moduleTitle=Chin J Cancer Res：中肿徐瑞华教授团队IV期观察性研究：评估中国转移性结直肠癌使用化疗联合贝伐珠单抗治疗的真实世界疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a7d292555c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477110, encodeId=de8214e7110a7, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=J Hepatol: Atezolizumab联合贝伐珠单抗vs索拉非尼治疗不可切除肝细胞癌的疗效更新：IMbrave150, objectType=article, longId=292266, objectId=82df292266f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82df292266f0, replyNumber=0, likeNumber=65, createdTime=2021-12-21, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82df292266f0, moduleTitle=J Hepatol: Atezolizumab联合贝伐珠单抗vs索拉非尼治疗不可切除肝细胞癌的疗效更新：IMbrave150, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82df292266f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477108, encodeId=aa8e14e7108fb, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, objectType=article, longId=292033, objectId=0686292033a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0686292033a0, replyNumber=0, likeNumber=64, createdTime=2021-12-18, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0686292033a0, moduleTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0686292033a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477107, encodeId=561a14e7107f4, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, objectType=article, longId=221315, objectId=ce4a22131527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4a22131527, replyNumber=0, likeNumber=89, createdTime=2021-12-01, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4a22131527, moduleTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4a22131527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477106, encodeId=fc8c14e7106b3, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗联合化疗在结直肠癌中的研究概况, objectType=article, longId=221260, objectId=7e602212604d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e602212604d, replyNumber=0, likeNumber=70, createdTime=2021-12-01, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e602212604d, moduleTitle=贝伐珠单抗联合化疗在结直肠癌中的研究概况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e602212604d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477105, encodeId=9aa314e710592, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=直肠癌转化治疗临床实战-FOLFOX+贝伐珠单抗, objectType=article, longId=221259, objectId=06bd221259a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06bd221259a2, replyNumber=0, likeNumber=62, createdTime=2021-12-01, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06bd221259a2, moduleTitle=直肠癌转化治疗临床实战-FOLFOX+贝伐珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06bd221259a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477104, encodeId=4f4d14e710453, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, objectType=article, longId=221101, objectId=e69e221101af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69e221101af, replyNumber=0, likeNumber=52, createdTime=2021-11-28, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69e221101af, moduleTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e69e221101af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477103, encodeId=8f0114e710317, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, objectType=article, longId=221028, objectId=979e22102878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979e22102878, replyNumber=0, likeNumber=48, createdTime=2021-11-27, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979e22102878, moduleTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=979e22102878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477102, encodeId=8fef14e710223, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=祝贺贝伐珠单抗在中国新增两项适应证, objectType=article, longId=220986, objectId=b1b1220986e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1b1220986e9, replyNumber=0, likeNumber=59, createdTime=2021-11-26, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1b1220986e9, moduleTitle=祝贺贝伐珠单抗在中国新增两项适应证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1b1220986e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477101, encodeId=d45814e710167, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”（妇科肿瘤）, objectType=article, longId=220796, objectId=e513220e9674, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e513220e9674, replyNumber=0, likeNumber=67, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e513220e9674, moduleTitle=贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”（妇科肿瘤）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e513220e9674)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477100, encodeId=06f714e710072, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”, objectType=article, longId=220784, objectId=5468220e84fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5468220e84fa, replyNumber=0, likeNumber=36, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5468220e84fa, moduleTitle=贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5468220e84fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477099, encodeId=d84d14e70990a, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐单抗联合免疫优选, objectType=article, longId=220778, objectId=43a6220e784f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a6220e784f, replyNumber=0, likeNumber=35, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a6220e784f, moduleTitle=贝伐单抗联合免疫优选, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43a6220e784f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477095, encodeId=f42814e7095c3, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=放疗联合贝伐珠单抗治疗肺腺癌脑转移瘤伴脑水肿的临床效果, objectType=article, longId=220776, objectId=2c90220e7682, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c90220e7682, replyNumber=0, likeNumber=61, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c90220e7682, moduleTitle=放疗联合贝伐珠单抗治疗肺腺癌脑转移瘤伴脑水肿的临床效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c90220e7682)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477094, encodeId=90b914e709474, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效, objectType=article, longId=220775, objectId=a95d220e7530, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a95d220e7530, replyNumber=0, likeNumber=68, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a95d220e7530, moduleTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a95d220e7530)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477093, encodeId=a57b14e7093c1, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的不良反应, objectType=article, longId=220774, objectId=fa70220e7438, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa70220e7438, replyNumber=0, likeNumber=62, createdTime=2021-11-23, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa70220e7438, moduleTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的不良反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa70220e7438)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477092, encodeId=c0a214e70928e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察, objectType=article, longId=220773, objectId=9a41220e7350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a41220e7350, replyNumber=0, likeNumber=55, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a41220e7350, moduleTitle=贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a41220e7350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477091, encodeId=624214e70918a, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清 VEGF水平的影响, objectType=article, longId=220772, objectId=5716220e7251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5716220e7251, replyNumber=0, likeNumber=57, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5716220e7251, moduleTitle=贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清 VEGF水平的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5716220e7251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477098, encodeId=29df14e709814, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗在NSCLC领域的主要研究（彭春雷）, objectType=article, longId=220756, objectId=c22e220e5698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c22e220e5698, replyNumber=0, likeNumber=36, createdTime=2021-11-23, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c22e220e5698, moduleTitle=贝伐珠单抗在NSCLC领域的主要研究（彭春雷）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c22e220e5698)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝伐

2020-05-29

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）

2022-01-27

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Cancers：真实世界研究表明在阿法替尼基础上加用贝伐珠单抗并不能显著改善EGFR敏感突变NSCLC患者的预后

2022-01-12

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Chin J Cancer Res：中肿徐瑞华教授团队IV期观察性研究：评估中国转移性结直肠癌使用化疗联合贝伐珠单抗治疗的真实世界疗效和安全性

2021-12-24

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

J Hepatol: Atezolizumab联合贝伐珠单抗vs索拉非尼治疗不可切除肝细胞癌的疗效更新：IMbrave150

2021-12-21

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好

2021-12-18

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌

2021-12-01

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗联合化疗在结直肠癌中的研究概况

2021-12-01

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

直肠癌转化治疗临床实战-FOLFOX+贝伐珠单抗

2021-12-01

智慧医人 (审核中...)

前往app查看评论内容

#贝伐#

Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性

2021-11-28

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益

2021-11-27

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

祝贺贝伐珠单抗在中国新增两项适应证

2021-11-26

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”（妇科肿瘤）

2021-11-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”

2021-11-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐单抗联合免疫优选

2021-11-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

放疗联合贝伐珠单抗治疗肺腺癌脑转移瘤伴脑水肿的临床效果

2021-11-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效

2021-11-23

hb2008ye (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的不良反应

2021-11-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察

2021-11-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗对肺腺癌脑转移伴难治性脑水肿患者生活质量及血清 VEGF水平的影响

2021-11-23

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗在NSCLC领域的主要研究（彭春雷）

2021-11-23

科室
- - 订阅+
  - 更多科室
工具
服务